Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
about
Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancerARID1A mutations in endometriosis-associated ovarian carcinomasWWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcomeClear cell carcinoma of the ovary: molecular insights and future therapeutic perspectivesDietary fat intake and ovarian cancer risk: a meta-analysis of epidemiological studiesPotential targets for ovarian clear cell carcinoma: a review of updates and future perspectivesOvarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reductionDNA methylation changes in epithelial ovarian cancer histotypes.Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatinNutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian CarcinomasIdentification of novel therapeutic targets in microdissected clear cell ovarian cancersAllelotype analysis of common epithelial ovarian cancers with special reference to comparison between clear cell adenocarcinoma with other histological types.Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis.Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma.IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.HNF-1β in ovarian carcinomas with serous and clear cell change.Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor.X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.Calculator for ovarian carcinoma subtype prediction.DNA copy numbers profiles in affinity-purified ovarian clear cell carcinomap21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens.Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer.PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.The cancer stem cell marker CD133 interacts with plakoglobin and controls desmoglein-2 protein levels.Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor developmentRECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cellsSomatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinomaPrognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
P2860
Q24307419-3C8FEC0A-7FEE-4779-B9B9-8C20ECA9FAF8Q24610484-B1835127-8C9B-41F2-9295-9CBD1F2D8CB0Q24815527-1839AC40-A220-4587-8BBD-6418924272E0Q26749280-2721B2E2-FA5C-404A-A7D4-340CDD389FCCQ26749395-DDA36DF4-FCBC-4009-91D4-4066C84E0759Q26775315-EF844135-2865-4B19-85E6-3B42AFB27ECFQ26786610-ED61F1D4-7A47-461D-BDA2-E95856F867A4Q27690722-E74112CB-ACEF-4132-86E6-C3DC1D9CE7A7Q28066904-B52FAE1D-6C3C-4698-B3BA-0185172A59C9Q28468340-A8754E34-906B-4336-94ED-B5E49258923AQ28547093-DAFF9BC1-9C13-485F-A239-D02EE3AB01D4Q28742873-B3229685-53AB-490A-9966-A7E793F70D3EQ30840095-01D001F8-B6A8-4659-AC9B-91523B0434E4Q31044907-CC45CC58-7DDE-4A60-B65A-787A032857F7Q31149715-5633D2AF-9AA7-4FCB-B783-EEBC9926ED54Q33404446-89BF6E8C-A644-435B-8A3A-3BD4F5C711B2Q33556447-D379CD5F-6CE9-4838-A092-4A35E93C3F51Q33563929-1ED51629-ECB7-41F7-88A9-777942E67102Q33580777-4D431BF5-0738-48CC-AB89-41E3509A4D3DQ33647555-71BA7581-3F0E-4F81-90F7-6E84FEB4E1FBQ33735170-CC83F3F5-4D66-4F61-82E7-C35CE6BE05E5Q33750160-54C4474B-D8D6-46B5-9D8B-867B05483F75Q33750177-6111230D-EF9B-4319-8012-E0353A3AC66FQ33763357-14B67F19-EE0A-4ADE-B0F9-AFB392F82918Q33767047-49483E57-2879-4720-896C-AB0A4AB16524Q33997928-F5DE55C1-874B-4857-A698-A3435719C3B8Q34290698-D7918BBA-DDCE-4822-B963-4F7B65CB06E4Q34305434-66FB1773-A948-496B-910B-81D9B4C13643Q34332205-2D300636-CEA0-4DC7-9D25-06B51444A18BQ34436731-AAC39650-7148-4DE9-99C9-FFFE21A82BADQ34528724-E915FC21-FAA2-43D7-BA47-21A60339C8C7Q34551692-32ACEF9E-82BE-41B9-8DAC-A5204E23FA0BQ34616645-211D455D-98B4-4A2F-B77A-7FC8FAD4B2ABQ34771886-7B35B8D1-0894-4083-BC50-DCD6500A825AQ34951783-68F58623-7466-487E-A92A-5DF31F9E6A74Q35051543-BA8401FB-B3A2-48A8-8772-B60057319950Q35057812-3D91446D-0014-476C-ADB4-8C187DABEF94Q35475560-FB011125-44DF-4568-A2ED-0775C3916537Q35545814-8E7B5BA4-5AFE-4721-82D2-0CA73AEF4147Q35612005-1C0D9B4D-FB00-4365-BBDF-5596EB873EF7
P2860
Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Clinical characteristics of cl ...... o platinum-based chemotherapy.
@ast
Clinical characteristics of cl ...... o platinum-based chemotherapy.
@en
type
label
Clinical characteristics of cl ...... o platinum-based chemotherapy.
@ast
Clinical characteristics of cl ...... o platinum-based chemotherapy.
@en
prefLabel
Clinical characteristics of cl ...... o platinum-based chemotherapy.
@ast
Clinical characteristics of cl ...... o platinum-based chemotherapy.
@en
P2093
P1433
P1476
Clinical characteristics of cl ...... o platinum-based chemotherapy.
@en
P2093
Sugiyama T
Terakawa N
P304
P356
10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.3.CO;2-X
P407
P577
2000-06-01T00:00:00Z